Status:
COMPLETED
Complement-activating Anti-human Leucocyte Antigen Donor Specific Antibodies in Solid Organ Transplantation
Lead Sponsor:
Paris Translational Research Center for Organ Transplantation
Conditions:
Organ Transplant Recipients
Eligibility:
All Genders
Brief Summary
This project will involve a systematic literature review and meta-analysis of studies assessing the impact of complement-activating anti-Human Leukocyte Antigen (HLA) donor specific antibodies (DSA) o...
Detailed Description
BACKGROUND: Organ transplantation has emerged as the treatment of choice for patients with end-stage chronic disease, which is an increasing burden in industrialized and newly-industrializing societi...
Eligibility Criteria
Inclusion
- Study design:
- Studies of any relevant design and in any language on the impact of complement-activating anti-HLA DSAs on long-term graft survival and/or the risk of rejection will be initially selected.
- eligible studies: The eligible studies include all solid organ transplant patients (kidney, liver, lung, heart, and intestinal transplantation), both adult or paediatric patients.
- Measurement:
- Anti-HLA DSAs detect by the single antigen Luminex bead technique (SAB) will be required for the DSA detection technique. Complement-activating anti-HLA DSAs will be defined according to their ability to bind C1q, C3d, and C4d or their IgG3 subclass.
Exclusion
- Animal studies
- Ex vivo studies
- Methodological studies
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2018
Estimated Enrollment :
7547 Patients enrolled
Trial Details
Trial ID
NCT03438058
Start Date
January 1 2017
End Date
February 1 2018
Last Update
February 19 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.